Asston Pharmaceuticals IPO Listed at 3.25% Discount on BSE at ₹119

On the last day, the Asston Pharmaceuticals IPO subscribed 186.55 times overall, while the retail quota was subscribed 172.06 times, QIB 85.76 times, and the NII quota 353.14 times, respectively. 

Asston Pharmaceuticals IPO Details 

Asston Pharmaceuticals received approval from SEBI for its IPO of ₹27.56 crores, a fresh issue of ₹27.56 crores with a face value of ₹10 per share. It has a set price band of ₹115 to ₹123 Per Share.  

Asston Pharmaceuticals Funds Utilisations 

• Funding capital expenditure requirements for acquiring machinery in the manufacturing unit
• Funding the incremental working capital requirements of the Company
• Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
• General Corporate Purposes

Asston Pharmaceuticals Shares Distributions 

Moreover, the retail category had 2,000 shares in a 2-lot size, with a minimum application and a maximum application.

S-HNI got 3,000 shares in 3 lot sizes. 

To participate in this IPO, each investor group has a tailored investment range

• Retail Minimum Application:- ₹2,46,000
• Retail Maximum Application:-₹2,46,000
• S-Hni Application:- ₹3,69,000

Asston Pharmaceuticals Subscription Duration

Started on July 9, 2025, and closed on July 11, 2025. The allotment was on July 14, 2025. Asston Pharmaceuticals’ IPO listing is today, July 16, 2025. 

About Asston Pharmaceuticals IPO

Asston Pharmaceuticals Limited, founded in 2019, is a rapidly growing company operating in the pharmaceutical sector. It is also actively involved in the global export of healthcare products. The company offers a diverse portfolio that includes tablets, capsules, sachets, and syrups.

The company offers various products in therapeutic categories include analgesics, antibiotics, antifungals, vitamins, and more. Asston pharmaceutical is involved in the manufacturing of pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis mostly working on a principle-to-principle approach with various marketers. 

Asston Pharmaceutical Ltd is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. The company’s portfolio consists of many products such as Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen, Paracetamol, and Ferrovit Syrup.

Asston Pharmaceuticals IPO Financial Background

The company’s revenue of ₹25.61 crores in 2025, in contrast to 2024, was ₹15.84 crores. Moreover, the company reported a profit of ₹4.33 crores in 2025 against a profit of ₹1.36 crores in 2024.